Business Context and Reporting Period
This Form 8-K Current Report was filed by BioRestorative Therapies, Inc. on October 27, 2017. The filing primarily discloses the entry into a material definitive agreement involving a new debt financing arrangement and details several unregistered sales of equity securities that occurred between August and October 2017.
Key Financial Metrics and Capital Structure
The filing does not provide consolidated revenue, profit, cash flow, or margin data. Instead, it details specific financing activities and debt obligations:
- New Debt Financing: Issued a $675,000 promissory note to Tangiers Global, LLC, receiving $621,000 in net proceeds (with $54,000 retained as an original issue discount).
- Debt Terms: The Tangiers Note bears 6% guaranteed interest, matures on May 27, 2018, and is convertible at $2.75 per share.
- Equity Issuances: Issued 10,000 shares at $3.00/share; 25,168 shares for debt conversion ($56,219 value); 7,500 shares for loans; 4,300 shares for loan extensions; and 10,000 shares for services.
- Warrants Issued: Granted warrants for 40,663 shares (Tangiers), 10,000 shares (August transaction), 15,000 shares (loan consideration), and 38,118 shares (loan extension).
Material Changes and Transactions
Significant capital structure changes occurred during the reporting period:
- Debt Conversion: Converted $56,219 of outstanding indebtedness into 25,168 shares of common stock between September 27 and October 26, 2017.
- Loan Extensions: Extended maturity dates for certain loans in exchange for equity (4,300 shares) and warrants (38,118 shares) between October 1 and October 16, 2017.
- Convertible Notes: Issued $299,000 in convertible notes in connection with $275,000 of loans. These notes convert at 65% of fair market value, with a floor price of $1.00 per share.
- Service Compensation: Issued 10,000 shares valued at $20,000 for services rendered on September 13, 2017.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the inherent terms of the financial instruments. Key contingencies include:
- Conversion Risk: The Tangiers Note and other convertible notes allow lenders to convert debt to equity at prices that may be significantly below current market rates (e.g., 65% of fair market value), creating potential dilution.
- Liquidity Dependence: The company continues to rely on private placements and debt financing, including original issue discounts, to fund operations.
- Regulatory Compliance: All equity issuances relied on Section 4(a)(2) or Section 3(a)(9) exemptions from registration, assuming all investors were accredited.
Investor Verification Checklist
- Verify the total outstanding debt and the specific conversion prices of all convertible notes to assess potential dilution.
- Confirm the company's cash runway given the reliance on short-term debt (maturing May 2018) and the retention of funds for legal/due diligence expenses.
- Review the full text of Exhibits 10.1 and 10.2 for detailed covenants and adjustment mechanisms regarding the Tangiers Note and Warrant.
- Check subsequent filings for any default events or additional equity issuances related to the loans extended in October 2017.